Viking Therapeutics VKTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$359.64M-227% | -$109.96M-28.0% | -$85.9M-24.7% | -$68.87M-25.2% | ||
| $40.82M+37.4% | $29.71M+77.4% | $16.75M+93.1% | $8.67M+42.2% | ||
| -$278.69M-217% | -$87.79M-19.6% | -$73.38M-51.6% | -$48.4M-1.7% | ||
| $341.39M— | —— | —— | $54.75M+44.2% | ||
| $76.44M-87.5% | $612.46M+126% | $271.45M+6,421% | $4.16M-41.7% | ||
| $143.19M— | —— | —— | $10.52M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.